Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: Statin's advantage and the smoking "paradox"

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 5, 2009, Pages 368-372

  Motovska, Zuzana ^a   Widimsky, Petr ^a   Petr, Robert ^a   Bilkova, Dana ^a   Marinov, Iuri ^b   Simek, Stanislav ^c   Kala, Petr ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Cigarette smoke; Clopidogrel efficacy; Elective coronary angiography; Factors; Pretreatment; Smoking; Stable coronary artery disease; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; SIMVASTATIN; VASODILATOR STIMULATED PHOSPHOPROTEIN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CIGARETTE SMOKING; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG USE; FEMALE; FLOW CYTOMETRY; FLOW MEASUREMENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE;

AGE FACTORS; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BODY MASS INDEX; CELL ADHESION MOLECULES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MICROFILAMENT PROTEINS; PHOSPHOPROTEINS; PLATELET AGGREGATION INHIBITORS; RENAL INSUFFICIENCY; SEX FACTORS; SMOKING; TICLOPIDINE; TREATMENT OUTCOME;

EID: 67650901939     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31819d616b     Document Type: Article

References (26)

1. Eshaghian S, Kaul S, Amin S, et al. Role of clopidogrel in managing atherothrombotic cardiovascular disease. Ann Intern Med. 2007;146: 434-441. (Pubitemid 351650580)
2. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;27:2420-2425. (Pubitemid 44522148)
3. Widimsky P, Motovská Z, Simek S, et al; on behalf of the PRAGUE-8 trial Investigators. Clopidogrel pre-treatment in stable angina: for all patients >6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J. 2008;29:1495-1503.
4. Geiger J, Teichmann L, Grossmann R, et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem. 2005;51:957-965. (Pubitemid 40740875)
5. DavÌ G, Gresele P, Violi F, et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation. 1997;96:69-75.
6. Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007;115:708-716. (Pubitemid 46294761)
7. Wiviott SD, Trenk D, Frelinger AL, et al; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116:2923-2932
8. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21-30.
9. Bhatt DL, Fox KA, Hacke W, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-1717.
10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
11. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
12. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 1994;72:313-317. (Pubitemid 24251300)
13. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31:53-59.
14. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211-2221.
15. Bliden KP, Dichiara J, Lawal L, et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol. 2008; 52:531-533.
16. Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet. 1999;36:425-438.
17. Sweeney BP. Why does smoking protect against PONV? Br J Anaesth. 2002;89:810-813.
18. Weisz G, Cox DA, Garcia E, et al. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction - the smoker's paradox revisited. Am Heart J. 2005;150:358-364. (Pubitemid 41116264)
19. Katayama T, Iwasaki Y, Yamamoto T, et al. "Smoker's paradox" in patients with acute myocardial infarction receiving primary coronary intervention. J Cardiol. 2006;48:193-200.
20. Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost. 2008;6:54-61.
21. Motovska Y, Widimsky P, Petr R, et al; on behalf of the PRAGUE-8 trial Investigators. Optimal pretreatment timing for 600 mg clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectivity. Eur Heart J. 2008;29(Suppl):405. Abstract 2601.
22. Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol. 2006; 48:931-938. (Pubitemid 44292463)
23. Angiolillo DJ, Alfonso F. Clopidogrel statin interaction: myth or reality? J Am Coll Cardiol. 2007;50:296-298.
24. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003;107:32-37. (Pubitemid 36070929)
25. Neubauer H, Gunesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study. Eur Heart J. 2003;24:1744-1749. (Pubitemid 37236863)
26. Saw J, Brennan DM, Steinhubl SR, et al; CHARISMA Investigators. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol. 2007;50:291-295.